CSPC Pharmaceutical Group Limited (01093.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	56.8B	25.3B	29.5B	31.5B	31.6B
Cost of Revenue	17.3B	8.7B	8.9B	9.3B	8.9B
Gross Profit	39.5B	16.6B	20.7B	22.2B	22.7B
Operating Expenses
R&D Expense	11.4B	5.7B	5.3B	4.8B	4.1B
SG&A Expense	13.0B	7.3B	9.9B	10.4B	11.7B
General & Admin Expense	649.8M	825.5M	—	—	—
Selling & Marketing Expense	4.9B	6.5B	—	—	—
Other Expenses	2.3B	(198.4M)	—	—	—
Total Operating Expenses	26.7B	12.7B	15.2B	15.2B	15.8B
Cost and Expenses	44.0B	21.5B	24.1B	24.5B	24.7B
Operating Income (EBIT)	12.8B	3.9B	5.5B	7.0B	6.9B
Non-Operating
Interest Income	392.5M	190.8M	—	—	—
Interest Expense	73.1M	37.6M	43.7M	25.9M	24.9M
Net Interest Income	319.4M	153.2M	(43.7M)	(25.9M)	(24.9M)
Other Non-Op Income/Expense	1.1B	815.5M	229.7M	388.7M	811.6M
Non-Operating Income (excl Interest)	(179.5M)	—	(365.3M)	(468.9M)	(852.7M)
EBT (Pre-Tax Income)	14.0B	4.7B	5.7B	7.4B	7.7B
Income Tax Expense	2.5B	907.6M	1.3B	1.3B	1.4B
Bottom Line
Net Income	11.2B	3.8B	4.4B	5.9B	6.2B
Earnings from Cont. Ops	11.5B	3.8B	4.4B	6.1B	6.4B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	11.2B	3.8B	4.4B	5.9B	6.2B
Per Share
Basic EPS	HK$0.98	HK$0.33	HK$0.38	HK$0.50	HK$0.52
Diluted EPS	HK$0.98	HK$0.33	HK$0.38	HK$0.49	HK$0.52
Revenue Per Share	HK$4.99	HK$2.22	HK$2.52	HK$2.65	HK$2.65
Shares
Basic Shares Outstanding	11.4B	11.4B	11.7B	11.9B	11.9B
Diluted Shares Outstanding	11.4B	11.4B	11.7B	11.9B	11.9B
Profitability Metrics
EBITDA	16.3B	5.2B	7.2B	8.6B	8.9B
D&A	2.8B	1.4B	1.4B	1.1B	1.1B
EBIT	13.6B	3.9B	5.8B	7.5B	7.8B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026